clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Stomach Diseases D013272 7 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Skin Neoplasms D012878 12 associated lipids
Colitis D003092 69 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Arthritis D001168 41 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Abscess D000038 13 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Gastritis D005756 27 associated lipids
Heart Failure D006333 36 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Rodent Diseases D012376 4 associated lipids
Osteomyelitis D010019 10 associated lipids
Pancreatitis D010195 10 associated lipids
Skin Ulcer D012883 6 associated lipids
Cysts D003560 4 associated lipids
Urination Disorders D014555 9 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Bradycardia D001919 13 associated lipids
Endometriosis D004715 29 associated lipids
Myocardial Infarction D009203 21 associated lipids
Proteinuria D011507 30 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Arteriosclerosis D001161 86 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Fractures, Open D005597 3 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Fibrosis D005355 23 associated lipids
Tooth Discoloration D014075 7 associated lipids
Sinusitis D012852 9 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Enterocolitis, Pseudomembranous D004761 8 associated lipids
Psoriasis D011565 47 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Cross Infection D003428 9 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Wound Infection D014946 12 associated lipids
Bacteriuria D001437 7 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Periodontal Pocket D010514 9 associated lipids
Ischemia D007511 18 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Peptic Ulcer D010437 19 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Periodontitis D010518 22 associated lipids
Nasal Polyps D009298 26 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Dermatomycoses D003881 17 associated lipids
Fever D005334 35 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Bronchial Spasm D001986 18 associated lipids
Hyperlipidemias D006949 73 associated lipids
Bronchitis D001991 6 associated lipids
Shock, Septic D012772 11 associated lipids
Iritis D007500 2 associated lipids
Syphilis D013587 6 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Hearing Disorders D006311 10 associated lipids
Duodenitis D004382 4 associated lipids
Metaplasia D008679 7 associated lipids
Foot Diseases D005534 4 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Radiation Injuries D011832 14 associated lipids
Urticaria D014581 13 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
HIV Seropositivity D006679 15 associated lipids
Endophthalmitis D009877 12 associated lipids
Leprosy D007918 8 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Paronychia D010304 3 associated lipids
Dyspnea D004417 10 associated lipids
Pyelonephritis D011704 5 associated lipids
Angina Pectoris D000787 27 associated lipids
Klebsiella Infections D007710 7 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Stjepanovic MI et al. Pulmonary and Vertebral Mycobacterium avium Disease in a HIV-negative 71-year-old Man - A Case Report. 2016 Infez Med pmid:28011973
Muñoz-Egea MC et al. Effect of Antibiotics and Antibiofilm Agents in the Ultrastructure and Development of Biofilms Developed by Nonpigmented Rapidly Growing Mycobacteria. 2016 Microb. Drug Resist. pmid:26208145
Salimi A et al. Toxicity of macrolide antibiotics on isolated heart mitochondria: a justification for their cardiotoxic adverse effect. 2016 Xenobiotica pmid:26068526
Losurdo G et al. Role of concomitant therapy for eradication: A technical note. 2016 World J. Gastroenterol. pmid:27784977
Zycinska K et al. Antibiotic Treatment of Hospitalized Patients with Pneumonia Complicated by Clostridium Difficile Infection. 2016 Adv. Exp. Med. Biol. pmid:27620311
Bax HI et al. Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro. 2016 Antimicrob. Agents Chemother. pmid:26883697
Hirata Y et al. Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen. 2016 Int. J. Infect. Dis. pmid:27590563
Liou JM et al. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. 2016 Lancet pmid:27769562
Campillo A et al. [10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection]. 2016 Gastroenterol Hepatol pmid:27084668
Chauffour A et al. Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice. 2016 PLoS Negl Trop Dis pmid:27755552
Abuhammour A et al. Standard triple therapy versus sequential therapy for eradication of Helicobacter pylori in treatment naïve and retreat patients. 2016 Arab J Gastroenterol pmid:27665525
Matsumoto H et al. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. 2016 Dig. Dis. Sci. pmid:27659671
Zhou L et al. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial. 2016 Helicobacter pmid:26104022
Rossi A et al. Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. 2016 Drug Dev Ind Pharm pmid:26065531
Watanabe M et al. Saturated fatty acids and fatty acid esters promote the polymorphic transition of clarithromycin metastable form I crystal. 2016 Int J Pharm pmid:27553780
Nagashima A et al. Clarithromycin Suppresses Chloride Channel Accessory 1 and Inhibits Interleukin-13-Induced Goblet Cell Hyperplasia in Human Bronchial Epithelial Cells. 2016 Antimicrob. Agents Chemother. pmid:27550358
Couture G et al. [Second case of serum sickness-like reaction to claritrhomycin]. 2016 Presse Med pmid:27542759
Bugli F et al. In vitro effect of clarithromycin and alginate lyase against helicobacter pylori biofilm. 2016 Biotechnol. Prog. pmid:27535356
Shichijo S et al. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice. 2016 J Dig Dis pmid:27534444
Morimoto K et al. Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases. 2016 Ann Am Thorac Soc pmid:27513168
Christianson S et al. Time-to-Detection of Inducible Macrolide Resistance in Mycobacterium abscessus Subspecies and Its Association with the Erm(41) Sequevar. 2016 PLoS ONE pmid:27490181
Harada T et al. Premedication with Clarithromycin Is Effective against Secondary Bacterial Pneumonia during Influenza Virus Infection in a Pulmonary Emphysema Mouse Model. 2016 J. Pharmacol. Exp. Ther. pmid:27489022
Bonfigli AR et al. Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients. 2016 Nutr Metab Cardiovasc Dis pmid:27480449
Lotfipour F et al. Study of Antimicrobial Effects of Clarithromycin Loaded PLGA Nanoparticles against Clinical Strains of Helicobacter pylori. 2016 Drug Res (Stuttg) pmid:25919643
Lin LC et al. Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials. 2016 World J. Gastroenterol. pmid:27340362
Abd-Elsalam S et al. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. 2016 Medicine (Baltimore) pmid:27310977
De Francesco V et al. Two-week Triple Therapy with either Standard or High-dose Esomeprazole for First-line H. pylori Eradication. 2016 J Gastrointestin Liver Dis pmid:27308644
Miyaki A et al. An assessment of the efficacy of first-line Helicobacter pylori-eradication therapy based on clarithromycin susceptibility. 2016 Minerva Gastroenterol Dietol pmid:27304198
Okano Y et al. Miliary pulmonary nodules due to Mycobacterium xenopi in a steroid-induced immunocompromised patient successfully treated with chemotherapy: a case report. 2016 BMC Pulm Med pmid:27287608
Steurer J [Months of antibiotic therapy in persistent symptoms of Lyme disease without effect]. 2016 Praxis (Bern 1994) pmid:27269781
Chung JW et al. Ten-day empirical sequential or concomitant therapy is more effective than triple therapy for Helicobacter pylori eradication: A multicenter, prospective study. 2016 Dig Liver Dis pmid:27257049
Mitchell H and Katelaris P Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. 2016 Med. J. Aust. pmid:27256648
Ullah S et al. Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin. 2016 Drug Deliv pmid:27247018
Parize P et al. Induction therapy with linezolid/clarithromycin combination for Mycobacterium chelonae skin infections in immunocompromised hosts. 2016 J Eur Acad Dermatol Venereol pmid:25677464
Akram FE et al. A combination of silver nanoparticles and visible blue light enhances the antibacterial efficacy of ineffective antibiotics against methicillin-resistant Staphylococcus aureus (MRSA). 2016 Ann. Clin. Microbiol. Antimicrob. pmid:27530257
Kim JS et al. Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial. 2016 Gut Liver pmid:27114421
Manniello MD et al. Aerodynamic properties, solubility and in vitro antibacterial efficacy of dry powders prepared by spray drying: Clarithromycin versus its hydrochloride salt. 2016 Eur J Pharm Biopharm pmid:27106605
Fallone CA et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. 2016 Gastroenterology pmid:27102658
Bilgilier C et al. Prevalence of clarithromycin-resistant Helicobacter pylori strains in gastric mucosa-associated lymphoid tissue lymphoma patients. 2016 Ann. Hematol. pmid:27091350
Root AA et al. Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs. 2016 Br J Clin Pharmacol pmid:27090996
Kazama I et al. Clarithromycin Dose-Dependently Stabilizes Rat Peritoneal Mast Cells. 2016 Chemotherapy pmid:27088971
Huynh VA et al. [Fixed drug eruption to clarithromycin: The importance of challenge tests in diagnosis]. 2016 Ann Dermatol Venereol pmid:27080820
EmiralioÄŸlu N et al. Pulmonary Mycobacterium abscessus Infection in a Patient with Triple A Syndrome. 2016 J. Trop. Pediatr. pmid:27080471
Graham DY and Dore MP Helicobacter pylori therapy: a paradigm shift. 2016 Expert Rev Anti Infect Ther pmid:27077447
Song ZQ et al. Hybrid Therapy Regimen for Helicobacter Pylori Eradication. 2016 Chin. Med. J. pmid:27064046
Matsumoto H et al. Molecular Detection of H. pylori Using Adherent Gastric Mucous to Biopsy Forceps. 2016 Helicobacter pmid:27061611
Tsaganos T et al. Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis. 2016 Antimicrob. Agents Chemother. pmid:27044546
Murakami K et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. 2016 Gut pmid:26935876
Park JY et al. Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA. 2016 Dig. Dis. Sci. pmid:26923948
Guirao-Arrabal E et al. Clarithromycin plus linezolid as a sequential therapy for implantable-cardioverter-defibrillator infection caused by coagulase-negative staphylococci. 2016 Rev Esp Quimioter pmid:26888341
Friedman ND et al. Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort. 2016 Antimicrob. Agents Chemother. pmid:26883709
Chua CS et al. The efficacy of blueberry and grape seed extract combination on triple therapy for Helicobacter pylori eradication: a randomised controlled trial. 2016 Int J Food Sci Nutr pmid:26883189
Meng X et al. [Antibiotic resistance of Helicobacter pylori clinical isolates in Hebei Province]. 2016 Zhonghua Yi Xue Za Zhi pmid:26879786
Bakshi SS Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion. 2016 J Laryngol Otol pmid:26878377
Franceschi F et al. High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. pylori infection. 2016 Eur Rev Med Pharmacol Sci pmid:26875899
Tepeš B et al. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. 2016 Eur J Gastroenterol Hepatol pmid:26862930
Lim SG et al. The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. 2016 Dig Liver Dis pmid:26856963
Trac MH et al. Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. 2016 CMAJ pmid:26903359
Mukai S et al. Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines. 2016 Int. J. Oncol. pmid:26718641
Hirama T et al. PCR-Based Rapid Identification System Using Bridged Nucleic Acids for Detection of Clarithromycin-Resistant Mycobacterium avium-M. intracellulare Complex Isolates. 2016 J. Clin. Microbiol. pmid:26739154
Radheshi E et al. Postmortem diagnosis of anaphylaxis in presence of decompositional changes. 2016 J Forensic Leg Med pmid:26735898
Hassan ST et al. In vitro synergistic effect of Hibiscus sabdariffa aqueous extract in combination with standard antibiotics against Helicobacter pylori clinical isolates. 2016 Pharm Biol pmid:26731378
Çağan-Appak Y et al. Clarithromycin resistance and 23S rRNA gene point mutations of Helicobacter pylori infection in children. 2016 Turk. J. Pediatr. pmid:28276208
Thung I et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. 2016 Aliment. Pharmacol. Ther. pmid:26694080
Vermeer LM et al. Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. 2016 Drug Metab. Dispos. pmid:26668209
Meng Y et al. Multi-functional Liposomes Enhancing Target and Antibacterial Immunity for Antimicrobial and Anti-Biofilm Against Methicillin-Resistant Staphylococcus aureus. 2016 Pharm. Res. pmid:26666773
Kamiya K et al. Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori. 2016 J. Dermatol. pmid:26508502
Mark TM and Coleman M It's Time to Take Clarithromycin Seriously in Multiple Myeloma. 2016 Acta Haematol. pmid:26505907
Qiu XH et al. Clarithromycin Synergistically Enhances Thalidomide Cytotoxicity in Myeloma Cells. 2016 Acta Haematol. pmid:26505646
Hollitt A et al. Cat scratch disease of the parotid gland. 2016 Arch. Dis. Child. pmid:26403943
Oh B et al. The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial. 2016 Helicobacter pmid:26395781
Lee J et al. A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM. 2016 J. Matern. Fetal. Neonatal. Med. pmid:26373262
Tsujimae M et al. A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori. 2016 Digestion pmid:28030862
Takagi M et al. Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. 2015 Drug Metab. Pharmacokinet. pmid:26195223
Li Y et al. Liposomal co-delivery of daptomycin and clarithromycin at an optimized ratio for treatment of methicillin-resistant Staphylococcus aureus infection. 2015 Drug Deliv pmid:24471983
Jung IY et al. A case of bronchiolitis obliterans organizing pneumonia in an HIV-infected Korean patient successfully treated with clarithromycin. 2015 BMC Infect. Dis. pmid:26201392
Sobajima T et al. A Case of Pulmonary Actinomycosis Associated With Aspiration of Cedar Leaves. 2015 J Bronchology Interv Pulmonol pmid:26165898
Gunjan S et al. Clarithromycin enhances the antimalarial efficacy of mefloquine via its increased bioavailability and disrupting P. falciparum apicoplast. 2015 Life Sci. pmid:26164186
Zeng M et al. Clarithromycin and dexamethasone show similar anti-inflammatory effects on distinct phenotypic chronic rhinosinusitis: an explant model study. 2015 BMC Immunol. pmid:26047816
Converse PJ et al. Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease. 2015 PLoS Negl Trop Dis pmid:26042792
Klain V and Timmerman L Comment on The dangers of gastritis: a case of clarithromycin-associated brief psychotic episode. 2015 J. Nerv. Ment. Dis. pmid:26034875
Kim JS et al. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: A systematic review and meta-analysis. 2015 J. Gastroenterol. Hepatol. pmid:25867718
Heo J et al. Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial. 2015 J. Gastroenterol. Hepatol. pmid:25867608
Sugita S et al. EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells. 2015 Biochem. Biophys. Res. Commun. pmid:25858318
Kesselheim AS et al. Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. 2015 J Gen Intern Med pmid:25855479
Cowan R et al. Mycobacterium ulcerans treatment--can antibiotic duration be reduced in selected patients? 2015 PLoS Negl Trop Dis pmid:25658304
Brown-Elliott BA et al. Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs. 2015 J. Clin. Microbiol. pmid:25653399
Iino Y et al. Clinical effects of clarithromycin on persistent inflammation following Haemophilus influenzae-positive acute otitis media. 2015 Acta Otolaryngol. pmid:25649881
Kam Y et al. Sweat but no gain: inhibiting proliferation of multidrug resistant cancer cells with "ersatzdroges". 2015 Int. J. Cancer pmid:25156304
Yildizoglu U et al. Effect of antibiotic use on bacterial flora of tonsil core in patients with recurrent tonsillitis. 2015 Eur Arch Otorhinolaryngol pmid:25510984
Jiang F et al. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. 2015 Psychopharmacology (Berl.) pmid:25510856
Frew JW and Nguyen RT Tattoo-associated mycobacterial infections: an emerging public health issue. 2015 Med. J. Aust. pmid:26852055
Keshavarz Azizi Raftar S et al. The Helicobacter pylori resistance rate to clarithromycin in Iran. 2015 Microb. Drug Resist. pmid:25144338
Chan CC et al. Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia. 2015 BMC Gastroenterol pmid:26635102
Namkoong H et al. Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary Mycobacterium avium complex lesion: a case report. 2015 BMC Pulm Med pmid:26496968
Wang CH et al. Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China. 2015 World J. Gastroenterol. pmid:26494972
Kiesewetter B et al. Clarithromycin Leading to Complete Remission in the First-Line Treatment of Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma. 2015 J. Clin. Oncol. pmid:24778391
Yin SM et al. Disseminated Mycobacterium kansasii disease in complete DiGeorge syndrome. 2015 J. Clin. Immunol. pmid:26048260
Nakamura M et al. Clarithromycin ameliorates pulmonary inflammation induced by short term cigarette smoke exposure in mice. 2015 Pulm Pharmacol Ther pmid:26363279
Brusselle GG Are the antimicrobial properties of macrolides required for their therapeutic efficacy in chronic neutrophilic airway diseases? 2015 Thorax pmid:25870311